More Hep C drugs could halve mortality

Treating hepatitis C patients with new oral medications has the potential to significantly lower morbidity and mortality rates, according to research presented at Australian Gastroenterology Week.

It shows a fivefold increase in the uptake of sofosbuvir and other new medications would halve the number of hepatocellular carcinoma, decompensated cirrhosis and liver disease death cases by 2018.

This translates to an extra 13,500 people accessing the medications. But if the treatments are introduced at the current rate of 2,500 patients per year, morbidity and mortality would